Correlation Between Bristol Myers and Rapport Therapeutics,
Can any of the company-specific risk be diversified away by investing in both Bristol Myers and Rapport Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Bristol Myers and Rapport Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Bristol Myers Squibb and Rapport Therapeutics, Common, you can compare the effects of market volatilities on Bristol Myers and Rapport Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Bristol Myers with a short position of Rapport Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Bristol Myers and Rapport Therapeutics,.
Diversification Opportunities for Bristol Myers and Rapport Therapeutics,
-0.32 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Bristol and Rapport is -0.32. Overlapping area represents the amount of risk that can be diversified away by holding Bristol Myers Squibb and Rapport Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Rapport Therapeutics, and Bristol Myers is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Bristol Myers Squibb are associated (or correlated) with Rapport Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Rapport Therapeutics, has no effect on the direction of Bristol Myers i.e., Bristol Myers and Rapport Therapeutics, go up and down completely randomly.
Pair Corralation between Bristol Myers and Rapport Therapeutics,
Considering the 90-day investment horizon Bristol Myers Squibb is expected to under-perform the Rapport Therapeutics,. But the stock apears to be less risky and, when comparing its historical volatility, Bristol Myers Squibb is 4.01 times less risky than Rapport Therapeutics,. The stock trades about -0.01 of its potential returns per unit of risk. The Rapport Therapeutics, Common is currently generating about 0.01 of returns per unit of risk over similar time horizon. If you would invest 2,080 in Rapport Therapeutics, Common on October 9, 2024 and sell it today you would lose (281.00) from holding Rapport Therapeutics, Common or give up 13.51% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 29.49% |
| Values | Daily Returns |
Bristol Myers Squibb vs. Rapport Therapeutics, Common
Performance |
| Timeline |
| Bristol Myers Squibb |
| Rapport Therapeutics, |
Bristol Myers and Rapport Therapeutics, Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Bristol Myers and Rapport Therapeutics,
The main advantage of trading using opposite Bristol Myers and Rapport Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Bristol Myers position performs unexpectedly, Rapport Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rapport Therapeutics, will offset losses from the drop in Rapport Therapeutics,'s long position.| Bristol Myers vs. AbbVie Inc | Bristol Myers vs. Merck Company | Bristol Myers vs. Gilead Sciences | Bristol Myers vs. Johnson Johnson |
| Rapport Therapeutics, vs. CF Industries Holdings | Rapport Therapeutics, vs. Analog Devices | Rapport Therapeutics, vs. Paysafe | Rapport Therapeutics, vs. ServiceNow |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Other Complementary Tools
| Transaction History View history of all your transactions and understand their impact on performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |